Cardiovascular Risk‑Reduction Guidelines for Patients with Peripheral Artery Disease

Lipid‑Lowering Therapy

The ACC/AHA recommends high‑intensity statin therapy for all patients with PAD, aiming for an LDL‑C < 55 mg/dL and at least a 50 % reduction from baseline, regardless of initial cholesterol level. 1
Achieving the LDL‑C target with high‑intensity statins markedly lowers the incidence of myocardial infarction, stroke, and cardiovascular death in the PAD population. 1

Single‑agent antiplatelet therapy with clopidogrel 75 mg daily is preferred over aspirin for symptomatic PAD, providing greater reduction in myocardial infarction, stroke, and vascular death. 1

First‑line treatment for hypertension in PAD should be an ACE inhibitor or ARB, with a target systolic blood pressure of 120–129 mmHg. 1
In the HOPE trial, ramipril reduced the composite risk of myocardial infarction, stroke, or vascular death by 25 % in patients with PAD. 1
ACE inhibitors/ARBs confer cardiovascular protection beyond blood‑pressure lowering in PAD patients. 1
Systolic pressures < 120 mmHg are associated with increased major adverse cardiovascular events; therefore, overly aggressive lowering should be avoided. 1
Beta‑blockers are not contraindicated in PAD and may be used when indicated for coronary disease or heart failure, with minimal impact on walking distance. 2

At every clinical encounter, patients with PAD should receive counseling and combination pharmacotherapy (varenicline, bupropion, or nicotine‑replacement therapy) to quit smoking. [1][3]
Smoking cessation is the single most important modifiable factor for preventing PAD progression and limb loss. 3
Pharmacologic cessation aids achieve 1‑year abstinence rates of 16–30 % versus ~5 % with advice alone. 3
All three pharmacologic options are similarly effective and safe, with no evidence of increased cardiovascular events. 1
Ongoing smoking substantially raises the risk of death, myocardial infarction, and lower‑extremity amputation. 3

If claudication persists after smoking cessation and supervised exercise (≥30 min per session, ≥3 times/week for ≥12 weeks), add cilostazol 100 mg twice daily to improve walking distance. 1

For PAD patients with diabetes, SGLT2 inhibitors or GLP‑1 receptor agonists with proven cardiovascular benefit should be used, targeting an HbA1c < 7 %. 3
Intensive glucose control reduces microvascular complications (e.g., nephropathy, retinopathy) but has a modest effect on macrovascular events. 3

Routine dual antiplatelet therapy in stable PAD increases major bleeding without added cardiovascular benefit and should be avoided. 1
Targeting systolic blood pressure < 120 mmHg is linked to higher cardiovascular risk and should not be pursued. 1
Withholding beta‑blockers based on outdated concerns about worsening claudication is unwarranted. 2
Underestimating the importance of smoking cessation overlooks the most impactful intervention for PAD outcomes. 3

The European Society of Cardiology recommends prescribing clopidogrel 75 mg daily or aspirin 75-325 mg daily for antiplatelet therapy, high-intensity statin targeting LDL-C <55 mg/dL with ≥50% reduction from baseline, ACE inhibitor or ARB for blood pressure control targeting 120-129 mmHg systolic, SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit for diabetes management, and cilostazol 100 mg twice daily if claudication symptoms persist despite exercise therapy for older adults with PAD, smoking history, diabetes, hypertension, and hyperlipidemia 4, 5, 6

The American College of Cardiology recommends single antiplatelet therapy with clopidogrel 75 mg daily or aspirin 75-325 mg daily to reduce myocardial infarction, stroke, and vascular death in symptomatic PAD patients 4, 7, 8
The American Heart Association advises against using dual antiplatelet therapy routinely as it increases major bleeding risk without additional cardiovascular benefit in stable PAD 6

The European Society of Cardiology recommends high-intensity statin therapy for all PAD patients regardless of baseline cholesterol levels, targeting LDL-C <55 mg/dL and achieving ≥50% reduction from baseline 4, 5, 7
The American College of Cardiology suggests adding ezetimibe if the target is not achieved on maximally tolerated statin, and adding PCSK9 inhibitor if still not at goal on statin plus ezetimibe 4, 5

The American Heart Association recommends targeting systolic blood pressure 120-129 mmHg if tolerated to reduce cardiovascular disease risk, and using ACE inhibitors or ARBs as the preferred first-line agents for cardiovascular protection in PAD patients 4, 5, 7
The European Society of Cardiology advises using combination therapy with ACE inhibitors/ARBs plus diuretics and/or calcium channel blockers for difficult-to-control hypertension 5

The American Diabetes Association recommends using SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefit to reduce cardiovascular events independent of baseline HbA1c, and targeting HbA1c <7% to reduce microvascular complications 4, 5
The European Association for the Study of Diabetes suggests prioritizing glucose-lowering agents with proven cardiovascular benefits over agents without proven cardiovascular benefit or safety 4, 5

The American College of Cardiology recommends adding cilostazol 100 mg twice daily if claudication persists despite exercise therapy and smoking cessation, but notes that cilostazol does not reduce cardiovascular mortality or major cardiovascular events 9, 6

The American Heart Association recommends offering pharmacological therapy to all smokers with PAD, with varenicline, bupropion, and nicotine replacement therapy being equally effective options 6, 9, 10